"Orchestrating the future of life sciences"
Palo Alto-based lab automation software company orchestrating life science workflows via its aLab Suite platform, founded 2017, backed by Microsoft M12.
Artificial, Inc. is a Palo Alto, California-based software company founded in 2017 by David Fuller (CEO) and Nikhita Singh (CPO). The company develops the aLab Suite, a cloud-based digital orchestration platform designed to unify and automate laboratory operations in the life sciences industry.
The aLab Suite integrates robotics hardware, laboratory information management systems (LIMS), electronic lab notebooks (ELNs), and human workflows into a single interface. Key capabilities include autonomous scheduling of lab tasks, real-time monitoring, data capture, and AI-driven workflow optimization. The platform is designed to keep humans in the loop while dramatically reducing manual overhead in drug discovery and biotech research environments.
Artificial has notable pedigree: the founding team previously built tools for SpaceX ground control and LEGO Mindstorms, and developed cloud lab software before pivoting to life science orchestration. In May 2021, the company raised a $21.5M Series A round led by M12 (Microsoft's venture fund), with participation from Playground Global and AME Cloud Ventures. The company has also integrated NVIDIA BioNeMo NIM microservices to enable self-driving virtual screening workflows.
Artificial targets pharmaceutical companies, biotech startups, and contract research organizations (CROs) seeking to scale automated lab capacity. The company employs approximately 34-45 people.
Primary type & automation activities this supplier delivers:
Contact Artificial, Inc.
WEBSITE
https://www.artificial.comHEADQUARTERS
United States
Company Facts
Founded
2017
Primary Role
Software/Algorithm
Company Size
-
Primary Region
North America
Annual Sales
-
Funding Stage
-
Funding Total
-
WRC 2026 opens August 19 in Beijing with 300+ exhibitors, a first-ever SOE pavilion and a new Procurement Day, days after Unitree priced China's first mainland-listed humanoid robot IPO at a $9.04 billion valuation.
ByRobotToday Reporter Aug 08, 2026UCL and HKUST researchers, plus robotics CEOs, challenged embodied AI hype at WAIC 2026, citing generalization limits and no third-party evaluation standard.
ByThomas Siew Aug 03, 2026Pittsburgh Robotics Network's free Robotics & AI Discovery Day returns Sept 16, 2026 to the David L. Lawrence Convention Center — 250+ exhibitors and a new Defense Pavilion.
ByRobotToday Reporter Aug 02, 2026At WAIC 2026, AI-native platforms quietly replaced interpreter hardware — what invisible AI infrastructure means for robotics and embodied AI.
ByThomas Siew Jul 21, 2026WAIC 2026 named ten Flagship Exhibits from 3,000+ products — spanning domestic AI superclusters, humanoid robots, general-purpose agents, AI wearables, and protein design AI. Engineering breakdown by RobotToday.
ByThomas Siew Jul 20, 20262026 AI for Science landscape report: WAIC 2026 exhibitor breakdown, MIT Boltz-2 and CMU Coscientist case studies, US/China/EU policy comparison, Anthropic Claude Science, and US academic cautionary views.
ByThomas Siew Jul 19, 2026Comprehensive analysis of Vietnam's robotics industry: market size, industrial policy, key companies (Vingroup, Apicoo, Phenikaa-X), geopolitical dynamics, and 2030 growth opportunities.
ByKelly Stone Jun 09, 2026Construction musculoskeletal injuries cost US employers over $2 billion annually. Exoskeletons are moving from pilots to standard practice. Ottobock, German Bionic, Hyundai, and Innophys launched major products in 2024–2025. Korea and Japan lead adoption. AI is turning passive suits into connected safety platforms.
BySimon Dicky May 04, 2026The global counter-drone (C-UAS) sector is scaling fast. New EU and US factories, an ․87M US Army contract, and the 2026 FIFA World Cup deployment mark a turning point for autonomous anti-drone technology. Read RobotToday’s March 2026 briefing.
ByThomas Siew Mar 23, 2026By enabling rapid annotation of areas of interest in medical images, the tool can help scientists study new treatments or map disease progression.
ByLeona Tang Sep 27, 2025